

**Question for written answer E-000480/2023
to the Commission**
Rule 138
Virginie Joron (ID)

Subject: COVID-19: revelations by Dr Jordon Walker and Project Veritas about Pfizer, genome editing and toxic effects of the 'vaccine' on women

The Project Veritas whistle-blowers group posted two videos, one on 25 January 2023 and the other on 2 February 2023, containing a hidden-camera recording of senior member of Pfizer staff Dr Jordon Walker. In the videos, he says: 'We do these selected structure mutations to try and see if we can make them more potent.' 'Why don't we just mutate it ourselves so we could pre-emptively develop new vaccines?' 'Which, I suspect is the way that the virus started in Wuhan.'¹

'Because it has to be affecting something hormonal to impact menstrual cycles.' 'That is a little concerning.' 'All the government officials who review our drugs eventually come work for pharma companies. They're not going to be as harsh on the company.'

1. What is the position of the Commission and the EMA on the information disclosed in the videos?
2. With a view to preventing, reducing or eliminating the risk to Europeans' – and particularly women's – health, will the Commission and the EMA invite Dr Walker to give evidence about possible illegal or risky practices at Pfizer?
3. Will the Commission protect the whistle-blower² and use this evidence to cancel the delivery of half a billion doses planned for 2023 and 2024³?

Submitted: 15.2.2023

¹ Links to videos: https://twitter.com/Project_Veritas/status/1618405890612420609
https://twitter.com/Project_Veritas/status/1621296377446686725

² All whistle-blowers on health matters should be protected by the Commission. Health is one of the fields covered by Directive 2019/1937 on the protection of persons who report breaches of Union law, under recital 13 and Article 2(1)(a)(viii) (see: <https://eur-lex.europa.eu/legal-content/FR/TXT/PDF/?uri=CELEX:32019L1937&from=en?>).

³ Deliveries have been planned for 2024 despite Brussels recognising that there is a 'mismatch between supply and demand' and that Member States have 'no desire to spend money on unneeded doses' (see: <https://www.reuters.com/business/healthcare-pharmaceuticals/eu-may-pay-more-pfizer-covid-shots-return-lower-volume-2023-01-27/>).